Why the study?
Stent thrombosis is a fatal complication after PCI, but the association between P2Y12 reaction unit levels and stent thrombosis occurrence remains unclear.
Does high platelet reactivity predict early stent thrombosis and subsequent cardiovascular events in patients treated with clopidogrel after DES implantation?
Does high platelet reactivity predict early stent thrombosis and subsequent cardiovascular events in patients treated with clopidogrel after DES implantation?
High platelet reactivity on clopidogrel strongly predicts early stent thrombosis and subsequent adverse cardiovascular events after DES implantation.
Answers are grounded in this paper and cite their sources.
High on-clopidogrel platelet reactivity may flag early stent thrombosis risk after DES; leaves open whether reactivity-guided therapy improves outcomes.
Stent thrombosis (ST) is a fatal complication after percutaneous coronary intervention (PCI). The association between P2Y12 reaction unit (PRU) level and stent thrombosis occurrence remains unclear. Based on the multicenter, observational PTRG-DES (Platelet function and genoType-Related long-term proGnosis in DES-treated patients) registry of patients with drug-eluting stents (DES) implantation, a total of 11,714 patients with PRU values were analyzed. We sought to identify the predictors of early stent thrombosis (EST) and compared the primary outcome, a composite of cardiac death, myocardial infarction, and revascularization, between EST and non-EST groups. EST, defined as definite ST within 1 month after index PCI, occurred in 51 patients. PRU values were significantly higher in the EST group (263.5 ± 70.8 vs. 217.5 ± 78.7, p < 0.001). In multivariable analysis, PRU ≥ 252 (OR, 5.10; 95% CI 1.58-16.46; p = 0.006) and aspirin reaction unit ≥ 414 (OR 4.85; 95% CI 1.07-21.97; p = 0.040) were independent predictors of EST. The cumulative incidence of primary composite outcome at one year was significantly higher in the EST group (38.2% vs. 3.9%, Log-rank p < 0.001). In patients treated with clopidogrel after successful DES implantation, EST was associated with higher platelet reactivities, and a greater risk of cardiovascular events.Trial Registration: clinicaltrials.gov Identifier: NCT04734028.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: